Highbridge Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Highbridge Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-14,200	Closed	-$39K	–	1995
2017 Q4	$39K	Sell	14,200 -118,277	-89%	-$363K	﹤0.01%	1582
2017 Q3	$449K	Buy	132,477 +112,477	+562%	+$313K	0.01%	989
2017 Q2	$49K	Buy	+20,000	New	+$46K	﹤0.01%	1184
2016 Q4	–	Sell	-474,610	Closed	-$1.59M	–	1846
2016 Q3	$1.59M	Buy	+474,610	New	+$1.51M	0.03%	469
2016 Q1	–	Sell	-132,772	Closed	-$470K	–	2121
2015 Q4	$470K	Buy	+132,772	New	+$556K	0.01%	1016
2015 Q2	–	Sell	-481,528	Closed	-$3.39M	–	1925
2015 Q1	$3.39M	Sell	481,528 -33,077	-6%	-$240K	0.05%	404
2014 Q4	$3.97M	Sell	514,605 -219,786	-30%	-$1.74M	0.05%	347
2014 Q3	$5.49M	Buy	+734,391	New	+$6.82M	0.07%	287

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Highbridge Capital Management's PDLI Position: Q1 2018 in Review

Highbridge Capital Management sold out of PDL BioPharma, Inc. (PDLI) in Q1 2018, closing a stake of 14,200 shares — an estimated $39K sold.

Highbridge Capital Management first reported a position in PDLI in Q3 2014 and held it in 8 quarters. The position peaked at $5.49M in Q3 2014. 176 funds tracked by Wall St. Rank hold PDLI as of Q1 2018.

Highbridge Capital Management reported no remaining PDL BioPharma, Inc. position as of Q1 2018 after selling out during the quarter.
Highbridge Capital Management sold 14,200 PDL BioPharma, Inc. shares in Q1 2018, an estimated $39K.
Highbridge Capital Management first reported a position in PDL BioPharma, Inc. in Q3 2014 and held it in 8 quarters.
Highbridge Capital Management's PDL BioPharma, Inc. position peaked at $5.49M in Q3 2014.
176 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2018.

Based on Highbridge Capital Management's 13F filing for Q1 2018, filed 15 May 2018.